Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective

doi:10.3748/wjg.v20.i47.17737

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 47

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14564)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

1187

WORD

240

HTML

10090

Figures (1-2)

412

Sum=11929

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1255

Download

1380

Sum=2635

Dec 21, 2014 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (119)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Dec 21, 2014; 20(47): 17737-17745
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17737

Open in New Tab Full Size Figure Download Figure

Figure 1 Influence of the intestinal microbiota in promoting gut permeability and insulin resistance. Changes in the intestinal microbiota reduce tight junction proteins of gut epithelial cells and increase gut permeability, thus promoting metabolic endotoxemia and insulin resistance. LPS: Lipopolysaccharide.

Open in New Tab Full Size Figure Download Figure

Figure 2 Role of the intestinal microbiota in the pathogenesis of type 2 diabetes. The intestinal microbiota may play an important role in the onset of type 2 diabetes by influencing body weight, bile acid metabolism, proinflammatory activity, NAFLD and insulin resistance, and modulating gut hormones. NAFLD: Non-alcoholic fatty liver disease; SCFAs: Short-chain fatty acids; FXR: Farnesoid X receptor; GLP: Glucagon-like peptide; PYY: Peptide YY.

Citation: Han JL, Lin HL. Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World J Gastroenterol 2014; 20(47): 17737-17745
URL: https://www.wjgnet.com/1007-9327/full/v20/i47/17737.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i47.17737